1 completed, 1 terminated. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow SRF617: new trials by email Literature Review of SRF617 trials Research Report on SRF617
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer SRF617, etrumadenant, zimberelimab - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 2 | Terminated | Coherus Oncology, Inc. | 16 | 2022-01-17 | 2025-05-08 |
| Study of SRF617 in Patients With Advanced Solid Tumors SRF617, Gemcitabine, Albumin-Bound Paclitaxel - Advanced Solid Tumor | Phase 1 | Completed | Coherus Oncology, Inc. | 85 | 2020-03-16 | 2024-06-04 |
Neoplasms (2) · Lung Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Stomach Neoplasms (1)
Canada (2) · United States (2)
Alison O'Neill, MD (1) · Vienna Reichert, PhD (1)